Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hospira, a company engaged in generic injectable pharmaceuticals, has introduced a two-gram vial of Gemcitabine hydrochloride (HCL) for injection.
Subscribe to our email newsletter
Hospira‘s Gemcitabine is approved by the US Food and Drug Administration (FDA) for treatment of a variety of cancers.
Hospira claimed that it will be the first company to offer Gemcitabine in a two-gram vial for 180 days from the date of launch based on market exclusivity earned as the first company to file for this generic presentation of the drug.
Hospira US president Thomas Moore said that the company heard calls from physicians and pharmacists for a larger presentation of Gemcitabine in line with dosing practices, and they have met their needs.
"With this launch, we’ve expanded the availability of generic oncology offerings and added additional convenience for the medical community," Moore said.